Silence Therapeutics plc reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was GBP 3.37 million compared to GBP 3.16 million a year ago. Net loss was GBP 7.1 million compared to GBP 9.93 million a year ago. Basic loss per share from continuing operations was GBP 0.216 compared to GBP 0.333 a year ago.
For the nine months, sales was GBP 12.74 million compared to GBP 9 million a year ago. Net loss was GBP 26.73 million compared to GBP 29.98 million a year ago. Basic loss per share from continuing operations was GBP 0.864 compared to GBP 1.014 a year ago.